GC Green Cross Signs Joint Sales Agreement with Sanofi for Antiplatelet Drug 'Plavix'

[Asia Economy Reporter Myunghwan Lee] GC Green Cross announced on the 13th that it has signed a co-promotion partnership for sales and marketing of Sanofi-Aventis Korea's antiplatelet agent 'Plavix Tab 75mg' in the domestic clinic market.

This is the first time GC Green Cross and Sanofi have formed a partnership. Through this collaboration, GC Green Cross will be responsible for sales and marketing of Plavix Tab 75mg primarily targeting domestic clinics.

Plavix Tab 75mg is the original antiplatelet agent containing the active ingredient 'clopidogrel,' prescribed to patients with stroke, myocardial infarction, and peripheral arterial disease. The main ingredient, clopidogrel, inhibits the formation of blood clots to prevent the risk of recurrence in patients with acute coronary syndrome and is used to prevent related risks.

GC Green Cross explained that through this agreement, it expects synergy with its own products in the chronic disease area linked to dyslipidemia, diabetes, and hypertension, as well as in reducing the risks of stroke, myocardial infarction, and peripheral arterial disease. Recently, GC Green Cross has sequentially launched the triple combination drug 'Rozetel' and the quadruple combination drug 'Rozetelpine,' prescribed for dyslipidemia and hypertension.

A GC Green Cross official stated, "We will continue collaborations such as open innovation and co-promotion partnerships to provide various treatment options for managing risk factors in domestic chronic disease patients."

This content was produced with the assistance of AI translation services.